COLL

Colleen Tupper

Known title: EVP & Chief Financial OfficerCIK: 0001862082

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 15, 2026

COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.

this person other insiders at COLL

Transaction History

COLL▲ Buy$0
COLL▲ Buy$0
COLL▼ Sell$555K
COLL▼ Sell$1.2M
COLL▼ Sell$1.0M
COLL▼ Sell$201K
COLL▼ Sell$192K
COLL▼ Sell$36K
COLL▼ Sell$29K
COLL▼ Sell$313K
COLL▼ Sell$45K
COLL▼ Sell$58K
COLL▼ Sell$247K
COLL▼ Sell$681K
COLL▲ Buy$0
COLL▲ Buy$0
COLL▼ Sell$674K
COLL▼ Sell$568K
COLL▼ Sell$319K
COLL▲ Buy$0
COLL▲ Buy$0
COLL▼ Sell$752K
COLL▼ Sell$104K
COLL▼ Sell$186K
COLL▲ Buy—
COLL▲ Buy$0
COLL▼ Sell$75K
COLL▲ Buy$0
COLL▲ Buy—
COLL▼ Sell$50K
COLL▼ Sell$22K

We use analytics to understand how market-wall is used. No personal data is sold.